However, by way of using IHC alone, there is no fine subcategorization of cancers with a 3+ IHC score, and the correlation between the HER2 copy number and the response rate to anti-HER2 thus remains unclear, whatever the clinical setting. This evidence concerns the gene ERBB2 and cancer.